At the end of this period and to address the aforementioned gap in the literature, we decided to conduct a cohort study aiming to compare the efficacy of isCGM devices versus CBG in glycemic control of inpatient type 2 diabetes on intensive insulin therapy. The gene discussed is INS; the disease is type 2 diabetes mellitus.